Reply to ‘Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on “Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab”’
Clinical and Experimental Dermatology · 2023
DOI: 10.1093/ced/llad160 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Pablo López Sanz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Biosimilar Pharmaceuticals, Mevalonate Kinase Deficiency, Psoriasis. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
The management of patients with paradoxical hidradenitis suppurativa receiving biologic therapy should be individualized, but the treatment of these reactions is mainly based on the discontinuation of the culprit drug taking into account the balance between subsequent risks and benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Dermatology.
- Internal Medicine, University General Hospital of Albacete, Albacete, Spain.
- Departments of Dermatology and Internal Medicine, University General Hospital of Albacete, Albacete, Spain.
ORCID-Profile: Pablo López Sanz
Zitieren
APA
López Sanz, P., Guzmán Pérez, M., Guerrero Ramírez, C., Manso Córdoba, S., Alfaro Martínez, M. E., & Azaña Defez, J. M. (2023). Reply to ‘Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on “Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab”’. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad160
Vancouver
López Sanz P, Guzmán Pérez M, Guerrero Ramírez C, Manso Córdoba S, Alfaro Martínez ME, Azaña Defez JM. Reply to ‘Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on “Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab”’. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad160
BibTeX
@article{LpezSanz2023,
author = {López Sanz, Pablo and Guzmán Pérez, Marta and Guerrero Ramírez, Claudia and Manso Córdoba, Silvia and Alfaro Martínez, María Encarnación and Azaña Defez, José Manuel},
title = {Reply to ‘Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on “Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab”’},
journal = {Clinical and Experimental Dermatology},
year = {2023},
doi = {10.1093/ced/llad160}
}
EUVIMED